<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e6def323-179c-432e-957d-fc4ea03e1b78"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use AVMAPKI™ FAKZYNJA™ CO-PACK safely and effectively. See full prescribing information for AVMAPKI™ FAKZYNJA™ CO-PACK. <br/>
      <br/> AVMAPKI™ FAKZYNJA™ CO-PACK (avutometinib capsules; defactinib tablets), co-packaged for oral use <br/>
      <br/> Initial U.S. Approval: 2025</title>
   <effectiveTime value="20250501"/>
   <setId root="65889527-1406-45df-8a85-e2690dcf427d"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="032472566" root="1.3.6.1.4.1.519.1"/>
            <name>Verastem Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="73a76ab5-7ba7-4bfa-90a6-7c7317e450c7"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250501"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71779-623" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AVMAPKI FAKZYNJA CO-PACK</name>
                        <formCode code="C47916" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="KIT"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>avutometinib potassium and defactinib hydrochloride</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asContent>
                           <quantity>
                              <numerator value="1" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="71779-623-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250508"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <part>
                           <quantity>
                              <numerator value="24" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="71779-660" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>AVMAPKI</name>
                              <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>avutometinib potassium</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator value="0.8" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="223UH3FM7T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>avutometinib potassium</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="D0D4252V97" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>avutometinib</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="97.6" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="3OWL53L36A" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Mannitol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="1.5" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Magnesium stearate</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYPROMELLOSE, UNSPECIFIED</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Titanium Dioxide</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Water</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="660YQ98I10" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Potassium Chloride</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="5C69YCD2YJ" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Carrageenan</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Shellac</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="3K9958V90M" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>ALCOHOL</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="ND2M416302" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Isopropyl Alcohol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="8PJ61P6TS3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Butyl Alcohol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Propylene Glycol</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>AMMONIA</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>FERROSOFERRIC OXIDE</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <ingredientSubstance>
                                    <code code="WZH3C48M4T" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Potassium Hydroxide</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="24" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71779-660-02" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA219616" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250508"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="19" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">6766</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                        <part>
                           <quantity>
                              <numerator value="42" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <partProduct>
                              <code code="71779-630" codeSystem="2.16.840.1.113883.6.69"/>
                              <name>FAKZYNJA</name>
                              <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                              <asEntityWithGeneric>
                                 <genericMedicine>
                                    <name>defactinib hydrochloride</name>
                                 </genericMedicine>
                              </asEntityWithGeneric>
                              <ingredient classCode="ACTIM">
                                 <quantity>
                                    <numerator value="200" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="L2S469LM49" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>defactinib hydrochloride</name>
                                    <activeMoiety>
                                       <activeMoiety>
                                          <code code="53O87HA2QU" codeSystem="2.16.840.1.113883.4.9"/>
                                          <name>defactinib</name>
                                       </activeMoiety>
                                    </activeMoiety>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="368.9" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="PNR0YF693Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>MICROCRYSTALLINE CELLULOSE 102</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="184.7" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="EWQ57Q8I5X" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Lactose monohydrate</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="24" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="H8AV0SQX4D" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>SODIUM STARCH GLYCOLATE TYPE A</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <ingredient classCode="IACT">
                                 <quantity>
                                    <numerator value="8" unit="mg"/>
                                    <denominator value="1" unit="1"/>
                                 </quantity>
                                 <ingredientSubstance>
                                    <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Magnesium stearate</name>
                                 </ingredientSubstance>
                              </ingredient>
                              <asContent>
                                 <quantity>
                                    <numerator value="42" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71779-630-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <characteristic>
                                       <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                       <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                                    </characteristic>
                                 </subjectOf>
                              </asContent>
                           </partProduct>
                           <subjectOf>
                              <approval>
                                 <id extension="NDA219616" root="2.16.840.1.113883.3.150"/>
                                 <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                                 <author>
                                    <territorialAuthority>
                                       <territory>
                                          <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                       </territory>
                                    </territorialAuthority>
                                 </author>
                              </approval>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250508"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                                    <originalText>white to off-white</originalText>
                                 </value>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value value="1" xsi:type="INT"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value unit="mm" value="18" xsi:type="PQ"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <characteristic classCode="OBS">
                                 <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value xsi:type="ST">VS2</value>
                              </characteristic>
                           </subjectOf>
                           <consumedIn>
                              <substanceAdministration>
                                 <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                              </substanceAdministration>
                           </consumedIn>
                        </part>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA219616" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250508"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="6e789638-cc2f-4c5d-8515-803d1fb30694"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>AVMAPKI FAKZYNJA CO-PACK is indicated for the treatment of adult patients with <content styleCode="italics">KRAS</content>-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.</paragraph>
                  <paragraph>This indication is approved under accelerated approval based on tumor response rate and duration of response <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content> Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>AVMAPKI FAKZYNJA CO-PACK, a combination of avutometinib and defactinib, each kinase inhibitors, is indicated for the treatment of adult patients with <content styleCode="italics">KRAS</content>-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy.</paragraph>
                        <paragraph>This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. (<linkHtml href="#S1">1</linkHtml>,<linkHtml href="#S14">14</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="3acba119-b2c7-44c9-bb7d-05ece3152964"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>AVMAPKI 3.2 mg administered orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                           <item>FAKZYNJA 200 mg administered orally twice daily for the first 3 weeks of each 4-week cycle. (<linkHtml href="#S2.3">2.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="523abd20-cc80-4a91-a778-89c0220efdcd"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Patient Selection</title>
                     <text>
                        <paragraph>Select patients for the treatment of recurrent LGSOC with AVMAPKI FAKZYNJA CO-PACK based on the presence of a <content styleCode="italics">KRAS</content> mutation in tumor specimens <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                        <paragraph>An FDA-approved test for the detection of a <content styleCode="italics">KRAS</content> mutation in LGSOC for selecting patients for treatment with AVMAPKI FAKZYNJA CO-PACK is not available. </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="ac0d13da-600f-4693-ab86-69833817c7a5"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Eye Exams and Prophylactic Skin Medications</title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="9fcd4b2f-74a5-413b-b7fe-5f6a6ad28d51"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Ophthalmic Exams</content>
                              </paragraph>
                              <paragraph>Conduct a comprehensive ophthalmic exam at baseline, prior to cycle 2, and every three cycles thereafter regardless of baseline exam findings, and as clinically indicated <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="e2dca44b-3219-41a6-84b9-c357deadde68"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Prophylactic Medications for Skin Reactions</content>
                              </paragraph>
                              <paragraph>With initiation of and during at least the first 2 cycles of AVMAPKI FAKZYNJA CO-PACK administer <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>Topical corticosteroid (applied to the face, scalp, neck, upper chest and upper back) </item>
                                 <item>Systemic oral antibiotics</item>
                              </list>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="d87e54f0-fbf0-474e-8d24-32c51a3a8f24"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Recommended Dosage and Administration</title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="59889a2c-c285-43b5-9925-501d0403cdf4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">AVMAPKI Capsules</content>
                              </paragraph>
                              <paragraph>The recommended dosage of AVMAPKI capsules is 3.2 mg (four 0.8 mg capsules) taken orally twice weekly (Day 1 and Day 4) for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.</paragraph>
                              <paragraph>Take AVMAPKI at the same time with each dose. AVMAPKI should be taken with food <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Swallow capsules whole. Do not chew, break, or open the capsules.</paragraph>
                              <paragraph>If a dose of AVMAPKI is missed by more than 24 hours, skip the missed dose and take the next scheduled dose as prescribed. Do not take two doses at the same time to make up for a missed dose. If vomiting occurs after taking AVMAPKI, do not take an additional dose. Take the next scheduled dose as prescribed.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f8699bed-00e0-4cc7-a02a-1ba2c1139d1f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">FAKZYNJA Tablets</content>
                              </paragraph>
                              <paragraph>The recommended dosage of FAKZYNJA tablets is 200 mg (one tablet) taken orally twice daily for the first 3 weeks of each 4-week cycle until disease progression or unacceptable toxicity.</paragraph>
                              <paragraph>Take each dose of FAKZYNJA with food <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. Swallow tablets whole. Do not chew, break or crush the tablets.</paragraph>
                              <paragraph>If a dose of FAKZYNJA is missed by more than 6 hours, skip the missed dose and take the next scheduled dose as prescribed. Do not take two tablets at the same time to make up for a missed dose. If vomiting occurs after taking FAKZYNJA, do not take an additional dose. Take the next scheduled dose as prescribed.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="77fde710-6011-46cb-8065-274c48bc9a06"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Dosage Modifications for Adverse Reactions</title>
                     <text>
                        <paragraph>Dose reductions due to adverse reactions due to AVMAPKI FAKZYNJA CO-PACK are summarized in Table 1.</paragraph>
                        <table width="85%">
                           <caption>Table 1 Recommended Dose Reductions for Adverse Reactions</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="35%" align="left" valign="top"/>
                           <col width="40%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Dose Level</th>
                                 <th styleCode="Rrule">AVMAPKI Capsule</th>
                                 <th styleCode="Rrule">FAKZYNJA Tablet</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Starting dose</td>
                                 <td styleCode="Rrule">3.2 mg twice weekly for first 3 weeks of each 4-week cycle</td>
                                 <td styleCode="Rrule">200 mg twice daily for first 3 weeks of each 4-week cycle</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Dose reduction</td>
                                 <td styleCode="Rrule">2.4 mg twice weekly for first 3 weeks of each 4-week cycle</td>
                                 <td styleCode="Rrule">200 mg once daily for first 3 weeks of each 4-week cycle</td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode="Lrule Rrule" align="center">Permanently discontinue both AVMAPKI and FAKZYNJA in patients unable to tolerate after one dose reduction of both products.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Dosage modifications for adverse reactions to AVMAPKI FAKZYNJA CO-PACK are summarized in Table 2.</paragraph>
                        <table width="90%">
                           <caption>Table 2 AVMAPKI FAKZYNJA CO-PACK Dosage Modifications</caption>
                           <col width="40%" align="left" valign="top"/>
                           <col width="20%" align="left" valign="top"/>
                           <col width="40%" align="left" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                 <th align="center" styleCode="Rrule">Severity<footnote>Severity as defined by National Center Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0</footnote>
                                 </th>
                                 <th align="center" styleCode="Rrule">Dose Modification</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="3">N/A: Not applicable</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">
                                    <content styleCode="bold">Keratitis</content>
                                    <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Confluent superficial keratitis, a cornea epithelial defect, or 3-line or more loss in best corrected distance visual acuity</td>
                                 <td styleCode="Rrule">Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to nonconfluent superficial keratitis, then resume at same dose.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Corneal ulcer or stromal opacity or best corrected distance visual acuity 20/200 or worse Corneal perforation</td>
                                 <td styleCode="Rrule Botrule">Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to nonconfluence superficial keratitis, then resume at reduced dose.<br/>Permanently discontinue  AVMAPKI FAKZYNJA CO-PACK.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">
                                    <content styleCode="bold">Blurred vision</content>
                                    <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">BCVA worse than baseline but no worse than 20/200</td>
                                 <td styleCode="Rrule">Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to baseline or 20/40, whichever is worse, then resume treatment at same dose.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">BCVA 20/200 or worse</td>
                                 <td styleCode="Rrule Botrule">Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to baseline or 20/40, whichever is worse, then resume at reduced dose.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="2">
                                    <content styleCode="bold">Conjunctivitis</content>
                                    <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Confluent superficial punctate staining, moderate to severe vasodilation</td>
                                 <td styleCode="Rrule">Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to nonconfluent superficial keratitis, then resume at same dose.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Conjunctival ulcer or neovascularization</td>
                                 <td styleCode="Rrule Botrule">Withhold AVMAPKI FAKZYNJA CO-PACK until resolution to nonconfluent superficial keratitis, then resume at reduced dose.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Retinal Pigment Epithelial (RPE) Detachment</content>
                                    <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">N/A</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="underline">First occurrence</content>
                                    <list listType="unordered" styleCode="disc">
                                       <item>Repeat Optical Coherence Tomography (OCT) examination in two weeks.</item>
                                    </list>
                                    <content styleCode="underline">First follow-up OCT examination and RPE present</content>
                                    <list listType="unordered" styleCode="disc">
                                       <item>Reduce dose of AVMAPKI FAKZYNJA CO-PACK</item>
                                       <item>Repeat OCT examination in two weeks.</item>
                                    </list>
                                    <content styleCode="underline">Second follow-up OCT examination and RPE present and/or loss of 1 line in BCVA</content>:<list listType="unordered" styleCode="disc">
                                       <item>Withhold AVMAPKI FAKZYNJA CO-PACK</item>
                                       <item>Repeat OCT examination in two weeks.</item>
                                    </list>
                                    <content styleCode="underline">Third follow-up OCT examination</content>
                                    <list listType="unordered" styleCode="disc">
                                       <item>RPE resolving/resolved, resume at reduced dose.</item>
                                       <item>No resolution, permanently discontinue AVMAPKI FAKZYNJA CO-PACK </item>
                                    </list>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="3">
                                    <content styleCode="bold">Rash</content>
                                    <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade ≤ 2</td>
                                 <td styleCode="Rrule">Consider withholding AVMAPKI FAKZYNJA CO-PACK if rash does not respond to supportive care or recurs after resolution to Grade ≤1.<br/>Dose reduce AVMAPKI FAKZYNJA CO-PACK for intolerable Grade 2.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Grade 3</td>
                                 <td styleCode="Rrule Botrule">Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to Grade 2 then resume at reduced dose. Resume at same dose if resolved to Grade ≤1.<br/>Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for recurrent Grade 3 despite dose reduction.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Grade 4</td>
                                 <td valign="middle" styleCode="Rrule Botrule">Permanently discontinue AVMAPKI FAKZYNJA CO-PACK.</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="3">
                                    <content styleCode="bold">Hepatotoxicity</content>
                                    <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 2</td>
                                 <td styleCode="Rrule">Withhold AVMAPKI FAKZYNJA CO-PACK for 											<list listType="unordered" styleCode="disc">
                                       <item>Grade 2 hyperbilirubinemia (without Gilbert's syndrome) with Grade ≤1 increase in AST and/or ALT until hyperbilirubinemia Grade ≤1, then resume at same dose.</item>
                                       <item>Grade 2 hyperbilirubinemia with Grade 2 increase in AST and/or ALT until hyperbilirubinemia Grade ≤1 or baseline, then resume at same dose.</item>
                                    </list>											Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for Grade 2 hyperbilirubinemia associated with Grade &gt;2 increase in AST and/or ALT. 											</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Grade 3</td>
                                 <td styleCode="Rrule Botrule">Withhold AVMAPKI FAKZYNJA CO-PACK 											<list listType="unordered" styleCode="disc">
                                       <item>if Grade 3 hyperbilirubinemia is associated with Grade ≤1 increase in AST and/or ALT until hyperbilirubinemia Grade ≤1 or at baseline, then resume at same dose.</item>
                                       <item>if recurrent Grade 3 hyperbilirubinemia is associated with Grade ≤1 increase in AST and/or ALT until hyperbilirubinemia Grade ≤2 or at baseline, then resume at reduced dose.</item>
                                       <item>if Grade 3 increased AST and/or ALT is not associated with hyperbilirubinemia until Grade ≤2 or at baseline, then resume at reduced dose. </item>
                                    </list>											Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for Grade 3 hyperbilirubinemia associated with Grade ≥2 increase in AST and/or ALT. 											</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Grade 4</td>
                                 <td styleCode="Rrule Botrule">Withhold AVMAPKI FAKZYNJA CO-PACK for 											<list listType="unordered" styleCode="disc">
                                       <item>Grade 4 hyperbilirubinemia associated with Grade ≤1 increase in AST and/or ALT and if resolves within one week resume at reduced dose.</item>
                                    </list>											Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for 											<list listType="unordered" styleCode="disc">
                                       <item>Grade 4 increase in AST and/or ALT.</item>
                                       <item>Grade 4 hyperbilirubinemia associated with Grade ≤1 increase in AST and/or ALT that does not resolve within 1 week.</item>
                                    </list>											Grade 4 hyperbilirubinemia associated with Grade ≥2 increase in AST and/or ALT. 											</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="3">
                                    <content styleCode="bold">Increased Blood Creatine Phosphokinase (CPK)</content>
                                    <br/>
                                    <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 3</td>
                                 <td styleCode="Rrule">Withhold AVMAPKI FAKZYNJA CO-PACK, if improves to Grade ≤1 within three weeks resume at same dose.<br/>Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for CPK elevation longer than three weeks.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Grade 4</td>
                                 <td styleCode="Rrule Botrule">Withhold AVMAPKI FAKZYNJA CO-PACK, if improves to Grade ≤1 within three weeks resume at reduced dose.<br/>Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for CPK elevation longer than three weeks.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Any grade CPK elevation with rhabdomyolysis or other event related to CPK elevation</td>
                                 <td styleCode="Rrule Botrule">Permanently discontinue AVMAPKI FAKZYNJA CO-PACK</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" rowspan="3">
                                    <content styleCode="bold">Other Adverse Reactions</content>
                                 </td>
                                 <td styleCode="Rrule">Grade 2</td>
                                 <td styleCode="Rrule">Consider withholding AVMAPKI FAKZYNJA CO-PACK if adverse reaction does not respond to supportive care or recurs after resolution to Grade ≤1.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule">Grade 3</td>
                                 <td styleCode="Rrule Botrule">
                                    <content styleCode="underline">First occurrence:</content>
                                    <br/>Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to baseline or Grade ≤1 then resume at same dose.<br/>
                                    <content styleCode="underline">Second occurrence:</content>
                                    <br/>Withhold AVMAPKI FAKZYNJA CO-PACK until resolved to baseline or Grade ≤1 then resume at reduced dose.<br/>Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for recurrent Grade 3 despite dose reduction.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule">Grade 4</td>
                                 <td valign="middle" styleCode="Rrule">Permanently discontinue AVMAPKI FAKZYNJA CO-PACK.</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="8ce851eb-a42b-4a31-b7f3-32432710b607"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>AVMAPKI FAKZYNJA CO-PACK is AVMAPKI (avutometinib) capsules co-packaged with FAKZYNJA (defactinib) tablets.</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>AVMAPKI capsules contain 0.8 mg avutometinib and are white capsules with "6766" printed on the cap and the strength "0.8 mg" printed on the body in black ink.</item>
                     <item>FAKZYNJA tablets contain 200 mg defactinib and are white to off-white tablets, oval and debossed with "VS2" on one side.</item>
                  </list>
               </text>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>AVMAPKI Capsules: 0.8 mg of avutometinib (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item>FAKZYNJA Tablets: 200 mg of defactinib (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="36a6c84d-8373-4eae-9a3f-0c937d15aeab"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="fdf6a149-8424-4946-9ac2-c3c2fb6addd3"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Ocular Toxicities:</content> Ocular toxicities, including visual impairment and vitreoretinal disorders, occurred. Perform comprehensive ophthalmic evaluation at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Withhold AVMAPKI FAKZYNJA CO-PACK for ocular toxicities until improvement at the same or reduced dose. Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for any grade 4 toxicity. (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Serious Skin Toxicities</content>: Skin toxicities, including photosensitivity and severe cutaneous adverse reactions (SCARs), occurred. Adhere to concomitant medications. Monitor for skin toxicities and interrupt, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity, tolerability and duration. (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity</content>: Monitor liver function tests prior to each cycle, on day 15 of the first 4 cycles, and as clinically indicated. Withhold, reduce or discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of abnormality. (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Rhabdomyolysis:</content> Monitor creatine phosphokinase prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reaction. (<linkHtml href="#S2.4">2.4</linkHtml>, <linkHtml href="#S5.4">5.4</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: AVMAPKI FAKZYNJA CO-PACK can cause fetal harm. Advise patients of the potential risk to a fetus and to use effective contraception. (<linkHtml href="#S5.5">5.5</linkHtml>, <linkHtml href="#S8.1">8.1</linkHtml>, <linkHtml href="#S8.3">8.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="385f71ab-5c79-49bd-a913-584544d83440"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Ocular Toxicities</title>
                     <text>
                        <paragraph>AVMAPKI FAKZYNJA CO-PACK can cause ocular adverse reactions, including visual impairment and vitreoretinal disorders.</paragraph>
                        <paragraph>Ocular adverse reactions occurred in 68% of patients with recurrent LGSOC treated with AVMAPKI FAKZYNJA CO-PACK. Common ocular adverse reactions (≥ 5%) were visual impairment (38%), dry eye (13%), orbital/periorbital edema (8%), and vitreous floaters (5%). Thirty-five patients (26%) experienced vitreoretinal disorders, including retinal detachment (9%), and retinal vein occlusion (0.7%). Eighteen patients (13%) experienced an ocular adverse reaction that resulted in dose interruption of AVMAPKI FAKZYNJA CO-PACK and one patient experienced an ocular adverse reaction that resulted in dose reduction.</paragraph>
                        <paragraph>The median time to onset of symptomatic ocular adverse reactions was 5 days (range 1 to 943 days) and to onset of asymptomatic ocular adverse reactions was 112 days (range 23 to 943 days). The median time to onset of retinal detachment was 27 days (range 2 to 535 days). Of the patients who experienced ocular adverse reactions, 29% had ongoing ocular events at last follow-up.</paragraph>
                        <paragraph>Refer patients to a qualified eye care professional for a comprehensive ophthalmic exam at baseline, prior to cycle 2, every three cycles thereafter, and as clinically indicated. Promptly refer patients to an eye care professional for any new or worsening ocular signs or symptoms.</paragraph>
                        <paragraph>Monitor for ocular adverse reactions and withhold, reduce, or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence of ocular adverse reactions <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="caca8f2a-c37b-406f-9cbc-3a95827930ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Serious Skin Toxicities</title>
                     <text>
                        <paragraph>AVMAPKI FAKZYNJA CO-PACK can cause serious skin toxicities, including Severe Cutaneous Adverse Reactions (SCARs). Cases of acute generalized exanthematous pustulosis, erythema multiforme and drug reaction with eosinophilia and systemic symptoms have been reported in clinical trials of avutometinib (a drug in AVMAPKI FAKZYNJA CO-PACK).</paragraph>
                        <paragraph>Skin toxicities occurred in 94% of patients with recurrent LGSOC treated with AVMAPKI FAKZYNJA CO-PACK. The most common skin toxicities (≥ 10%) were rash (67%), dermatitis acneiform (43%), dry skin (43%), pruritus (32%), and photosensitivity (13%). Grade 3 skin reactions occurred in 12% of patients including dermatitis acneiform (7%), rash (7%), and pruritus (1.5%). Thirteen patients (10%) developed bacterial skin infections. Skin toxicity led to dose interruption of AVMAPKI FAKZYNJA CO-PACK in 10%, to dose reduction in 7%, and to permanent discontinuation in 0.7% of patients. The median time to onset of the first skin toxicity was 14 days (range 1 to 500 days). At last follow-up, 66% of patients had ongoing skin toxicity.</paragraph>
                        <paragraph>Patients in RAMP-201 used topical corticosteroids (applied to the face, scalp, neck, upper chest and upper back) and systemic oral antibiotics for prophylaxis of skin adverse reactions. These medications were initiated at the start of AVMAPKI FAKZYNJA CO-PACK and administered during at least the first two cycles of treatment.</paragraph>
                        <paragraph>Limit unnecessary exposure to sunlight and apply daily sunscreen (sun protection factor [SPF] ≥ 30). Monitor for skin toxicity and withhold, reduce dose, or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and persistence <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="d6905b9e-1047-4158-a12b-1851ba959dfb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Hepatotoxicity</title>
                     <text>
                        <paragraph>AVMAPKI FAKZYNJA CO-PACK can cause hepatotoxicity.</paragraph>
                        <paragraph>In patients with recurrent LGSOC who received AVMAPKI FAKZYNJA CO-PACK, increased AST (73%), bilirubin (51%), ALT (49%), and alkaline phosphatase (46%) occurred. Grade 3-4 elevations in ALT was 3%, AST was 3%, bilirubin was 2.3% and alkaline phosphatase was 0.8%. Elevations in one or more liver related laboratory values led to dose interruption for 20%, dose reduction for 2.2%, and permanent discontinuation for 0.7% of patients.</paragraph>
                        <paragraph>Increased blood bilirubin may be attributed to defactinib (a component of AVMAPKI FAKZYNJA CO-PACK) due to the inhibition of enzymes responsible for metabolizing (uridine diphosphate-glucuronosyltransferase (UGT)1A1) and transporting (Organic Anion Transporting Polypeptides (OATP)1B1/1B3) bilirubin <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Monitor liver related laboratory values prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. Withhold, reduce dose, or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of these adverse reactions <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.4">
                     <id root="8a00943a-9c56-42a1-89b7-43e7499abf01"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Rhabdomyolysis</title>
                     <text>
                        <paragraph>AVMAPKI FAKZYNJA CO-PACK can cause increased creatine phosphokinase (CPK). Increased CPK occurred in 75% of patients with recurrent LGSOC treated with AVMAPKI FAKZYNJA CO-PACK, including Grade 3-4 elevations in 18% of patients. Among the patients who experienced an elevation in CPK, concurrent increase in creatinine occurred in 19% (n=19/102) and myalgia occurred in 10% (n=10/102). Elevation of CPK &gt;10 times the baseline value with a concurrent increase in serum creatinine of ≥1.5 times the baseline value occurred in 0.7% of patients. Increased CPK resulted in dose interruption for 22%, in dose reduction for 7%, and in discontinuation for 2.9% of patients. Rhabdomyolysis has occurred in a patient with LGSOC treated with AVMAPKI FAKZYNJA CO-PACK at the recommended dosage in a clinical trial.</paragraph>
                        <paragraph>Monitor CPK prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated. If increased CPK occurs, evaluate patients for rhabdomyolysis or other causes. Withhold, reduce or permanently discontinue AVMAPKI FAKZYNJA CO-PACK based on severity and duration of the adverse reactions <content styleCode="italics">[see <linkHtml href="#S2.4">Dose Modifications (2.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.5">
                     <id root="8211eb22-8593-4417-ab30-d4a8050b51ca"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Based on the mechanisms of action, AVMAPKI FAKZYNJA CO-PACK can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>. Inhibition of either molecular pathway has been associated with embryo-fetal anomalies and lethality in animals.</paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 1 month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 4 months after the last dose <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="89bb0db6-ec83-4c41-aa2b-bfcd3a658fe7"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in more detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Ocular Toxicities <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                     <item>Serious Skin Toxicities <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Hepatotoxicity <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                     <item>Rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common (≥ 25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Verastem at 1-833-633-8786 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="0b0f2eef-b359-4c53-990c-0446a4988fc7"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The pooled safety population described in Warnings and Precautions reflect exposure to the AVMAPKI FAKZYNJA CO-PACK (combination of AVMAPKI 3.2 mg twice weekly and FAKZYNJA 200 mg twice daily) for the first 3 weeks in a 4-week cycle until disease progression or unacceptable toxicity in 136 adult patients with recurrent LGSOC treated on RAMP-201 and FRAME (NCT03875820). The median duration of treatment was 10 months (range 0 to 51 months).</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="e0996f04-06f7-49d7-8d38-777fb6ff0e7d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">RAMP-201</content>
                              </paragraph>
                              <paragraph>The safety of AVMAPKI FAKZYNJA CO-PACK was evaluated in RAMP-201, a single-arm multicenter  trial in 57 patients with <content styleCode="italics">KRAS-</content>mutated recurrent LGSOC <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. Patients received AVMAPKI FAKZYNJA CO-PACK (AVMAPKI 3.2 mg twice weekly and FAKZYNJA 200 mg twice daily) for the first 3 weeks in a 4-week cycle until disease progression or unacceptable toxicity. The median duration of treatment was 12 months (range 0.03-40).</paragraph>
                              <paragraph>Serious adverse reactions occurred in 32% of patients who received AVMAPKI FAKZYNJA CO-PACK. The most common (≥2%) serious adverse reactions were sepsis (9%), intestinal obstruction (3.6%), pyelonephritis (3.6%), and hydronephrosis (3.6%). Fatal adverse reactions occurred in 3.6% of patients who received AVMAPKI FAKZYNJA CO-PACK, including intestinal obstruction (1.8%) and perforation (1.8%).</paragraph>
                              <paragraph>Permanent discontinuation of AVMAPKI FAKZYNJA CO-PACK due to an adverse reaction occurred in 14% of patients. The adverse reactions leading to permanent discontinuation included elevations in creatine phosphokinase, dyspnea, malaise, decreased glomerular filtration rate, hyperbilirubinemia,  increased alanine aminotransferase, and abdominal pain (1.8% each).</paragraph>
                              <paragraph>Dosage interruptions of AVMAPKI FAKZYNJA CO-PACK due to an adverse reaction occurred in 84% of patients. Adverse reactions which required dosage interruptions in ≥ 5% of patients included elevations in creatine phosphokinase (25%), hyperbilirubinemia (25%), diarrhea (12%), edema (11%), fatigue (9%), vision blurred (9%), vitreoretinal disorders (7%), transaminitis (7%), paronychia (5%), nausea (5%), abdominal pain (5%), vomiting (5%), dyspnea (5%), sepsis (5%), and rash (5%).</paragraph>
                              <paragraph>Dose reductions of AVMAPKI FAKZYNJA CO-PACK due to an adverse reaction occurred in 44% of patients. Adverse reactions which required dose reductions in ≥ 5% of patients were elevations in creatine phosphokinase (9%), fatigue (5%), hyperbilirubinemia (5%), and dermatitis acneiform (5%).</paragraph>
                              <paragraph>The most common (≥25%) adverse reactions, including laboratory abnormalities, were increased creatine phosphokinase, nausea, fatigue, increased aspartate aminotransferase, rash, diarrhea, musculoskeletal pain, edema, decreased hemoglobin, increased alanine aminotransferase, vomiting, increased blood bilirubin, increased triglycerides, decreased lymphocyte count, abdominal pain, dyspepsia, dermatitis acneiform, vitreoretinal disorders, increased alkaline phosphatase, stomatitis, pruritus, visual impairment, decreased platelet count, constipation, dry skin, dyspnea, cough, urinary tract infection, and decreased neutrophil count.</paragraph>
                              <paragraph>Table 3 summarizes the adverse reactions in RAMP-201.</paragraph>
                              <table width="85%">
                                 <caption>Table 3 Adverse Reactions (≥10%) in Patients with KRAS-Mutated Recurrent LGSOC who Received AVMAPKI FAKZYNJA CO-PACK in RAMP-201<footnote>Severity as defined by National Center Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0.</footnote>
                                 </caption>
                                 <col width="33%" align="left" valign="top"/>
                                 <col width="34%" align="center" valign="top"/>
                                 <col width="33%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Adverse Reaction</th>
                                       <th colspan="2" styleCode="Botrule Rrule">AVMAPKI FAKZYNJA CO-PACK<br/>N = 57</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">All Grades<br/>%</th>
                                       <th styleCode="Rrule">Grade 3 or 4<footnote>No Grade 4 treatment-emergent adverse events occurred.</footnote>
                                          <br/>%</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Gastrointestinal disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Nausea</td>
                                       <td styleCode="Rrule">74</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">68</td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">49</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Abdominal pain<footnote ID="Tb3ft">Includes multiple terms</footnote>
                                       </td>
                                       <td styleCode="Rrule">39</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspepsia<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">37</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Stomatitis<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">35</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Constipation</td>
                                       <td styleCode="Rrule">30</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dry mouth</td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased Weight</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">General disorders and administration site condition</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Fatigue<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">72</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Edema<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">67</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Rash<footnote>Includes: butterfly rash, dermatitis, drug eruption, erythema, rash, rash erythematous, rash macular, rash maculo-papular, rash papular, and rash pruritic</footnote>
                                       </td>
                                       <td styleCode="Rrule">72</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dermatitis acneiform<footnote>Includes: acne, dermatitis acneiform, folliculitis, perioral dermatitis, and rash pustular</footnote>
                                       </td>
                                       <td styleCode="Rrule">37</td>
                                       <td styleCode="Rrule">5.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pruritus<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">35</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dry skin<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">30</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Alopecia<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Photosensitivity<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Musculoskeletal pain<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">68</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Joint swelling</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Eye disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Vitreoretinal disorders<footnote>Includes: chorioretinopathy, detachment of retinal pigment epithelium, macular fibrosis, macular hole, maculopathy, retinal detachment, retinal drusen, retinal vein occlusion, retinopathy, serous retinal detachment, serous retinopathy, subretinal fluid, vitreous detachment, and vitreous floaters</footnote>
                                       </td>
                                       <td styleCode="Rrule">37</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Visual impairment<footnote>Includes: asthenopia, astigmatism, halo vision, metamorphopsia, photophobia, photopsia, vision blurred, visual field defect, and visual impairment</footnote>
                                       </td>
                                       <td styleCode="Rrule">35</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dry eye</td>
                                       <td styleCode="Rrule">12</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Respiratory disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspnea<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">26</td>
                                       <td styleCode="Rrule">5.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Cough</td>
                                       <td styleCode="Rrule">25</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Nervous system disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dizziness</td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Headache</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Neuropathy peripheral<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dysgeusia</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Vascular disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hemorrhage<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Hypertension</td>
                                       <td styleCode="Rrule">16</td>
                                       <td styleCode="Rrule">5.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Venous thromboembolism<footnoteRef IDREF="Tb3ft"/>
                                       </td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">5.3</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Metabolism and nutrition disorders</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased appetite</td>
                                       <td styleCode="Rrule">18</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Infections and infestations</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Urinary tract infection</td>
                                       <td styleCode="Rrule">25</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Paronychia</td>
                                       <td styleCode="Rrule">14</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Upper respiratory tract infection</td>
                                       <td styleCode="Rrule">11</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Clinically relevant adverse reactions in &lt; 10% of patients who received AVMAPKI FAKZYNJA CO-PACK included urticaria and decreased ejection fraction.</paragraph>
                              <paragraph>Table 4 summarizes the laboratory abnormalities in RAMP-201.</paragraph>
                              <table width="75%">
                                 <caption>Table 4 Select Laboratory Abnormalities (≥ 10%) in Patients with KRAS-Mutated Recurrent LGSOC who Received AVMAPKI FAKZYNJA CO-PACK in RAMP-201</caption>
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="15%" align="center" valign="top"/>
                                 <col width="35%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule">Laboratory Abnormality</th>
                                       <th colspan="2" styleCode="Botrule Rrule">AVMAPKI FAKZYNJA CO-PACK</th>
                                    </tr>
                                    <tr>
                                       <th styleCode="Lrule Rrule"/>
                                       <th styleCode="Rrule">All Grades<br/>(%)<footnote ID="Tb4ft">The denominator used to calculate the rate varied from 45 to 57 based on the number of patients with a baseline value and at least one post-treatment value.</footnote>
                                       </th>
                                       <th styleCode="Rrule">Grade 3 or 4<br/> (%)<footnoteRef IDREF="Tb4ft"/>
                                       </th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Chemistry</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased creatine phosphokinase</td>
                                       <td styleCode="Rrule">82</td>
                                       <td styleCode="Rrule">19</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased aspartate aminotransferase </td>
                                       <td styleCode="Rrule">70</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased albumin</td>
                                       <td styleCode="Rrule">70</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased alanine aminotransferase</td>
                                       <td styleCode="Rrule">58</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased blood bilirubin</td>
                                       <td styleCode="Rrule">48</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased triglycerides</td>
                                       <td styleCode="Rrule">46</td>
                                       <td styleCode="Rrule">3.5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Increased alkaline phosphatase</td>
                                       <td styleCode="Rrule">37</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased potassium</td>
                                       <td styleCode="Rrule">23</td>
                                       <td styleCode="Rrule">9</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td colspan="3" styleCode="Lrule Rrule">
                                          <content styleCode="bold">Hematology</content>
                                       </td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased hemoglobin</td>
                                       <td styleCode="Rrule">65</td>
                                       <td styleCode="Rrule">5</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased lymphocyte count</td>
                                       <td styleCode="Rrule">40</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased platelet count</td>
                                       <td styleCode="Rrule">35</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Decreased neutrophil count</td>
                                       <td styleCode="Rrule">25</td>
                                       <td styleCode="Rrule">1.8</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">
                                          <content styleCode="bold">Urine</content>
                                       </td>
                                       <td styleCode="Rrule"/>
                                       <td styleCode="Rrule"/>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Proteinuria</td>
                                       <td styleCode="Rrule">22</td>
                                       <td styleCode="Rrule">4.4</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Clinically relevant laboratory abnormalities in &lt; 10% of patients who received AVMAPKI FAKZYNJA CO-PACK included increased INR and prolonged activated partial thromboplastin time.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="b80640b5-9ee8-4b35-919a-290b6f9fc1b8"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Strong and moderate CYP3A4 inhibitors</content>: Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Strong and moderate CYP3A4 inducers</content>: Avoid concomitant use with AVMAPKI FAKZYNJA CO-PACK. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Warfarin</content>: Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin and use an alternative to warfarin. (<linkHtml href="#S7.2">7.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Gastric acid reducing agents</content>: Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid. (<linkHtml href="#S7.1">7.1</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S7.1">
                     <id root="391d1855-acc0-40fc-9abe-9daa9909d3ff"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Effect of Other Drugs on AVMAPKI FAKZYNJA CO-PACK</title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="662ce96b-2fe6-4e22-ad20-b6b2ef77f274"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Strong and Moderate CYP3A4 Inhibitors</content>
                              </paragraph>
                              <paragraph>Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with strong or moderate CYP3A4 inhibitors.</paragraph>
                              <paragraph>Defactinib is a CYP3A4 substrate. Concomitant use of defactinib with a strong CYP3A4 inhibitor increases defactinib exposure <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>],</content> which may increase the risk of AVMAPKI FAKZYNJA CO-PACK adverse reactions.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d4f659ac-c8b4-47dd-9ebe-0e8b8af00d3d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Strong and Moderate CYP3A4 Inducers</content>
                              </paragraph>
                              <paragraph>Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with strong or moderate CYP3A4 inducers.</paragraph>
                              <paragraph>Defactinib is a CYP3A4 substrate. Concomitant use of defactinib with a strong CYP3A4 inducer decreases defactinib exposure, which may reduce the effectiveness of FAKZYNJA <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="44e074fe-d41f-4cb0-909a-41f384750ba7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Gastric Acid Reducing Agents</content>
                              </paragraph>
                              <paragraph>Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with proton pump inhibitors (PPIs) or H2 receptor antagonists. If concomitant use of an acid-reducing agent cannot be avoided, administer FAKZYNJA 2 hours before or 2 hours after the administration of a locally acting antacid.</paragraph>
                              <paragraph>Concomitant use of FAKZYNJA with gastric acid reducing agents decreases defactinib exposure, which may reduce the effectiveness of AVMAPKI FAKZYNJA CO-PACK <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="eef31ca2-cd53-4a46-9aa3-61661f98f736"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Effect of AVMAPKI FAKZYNJA CO-PACK on Other Drugs </title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="5c00488c-80ae-4570-8090-2d6e328c777b"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics underline">Warfarin</content>
                              </paragraph>
                              <paragraph>Avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with warfarin.  For patients requiring anticoagulation, an alternative to warfarin is recommended. If concomitant use is unavoidable, monitor INR frequently during treatment with AVMAPKI FAKZYNJA CO-PACK.</paragraph>
                              <paragraph>Cases of bleeding and increased INR occurred in patients taking FAKZYNJA concomitantly with warfarin in clinical trials.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="218e9059-fac8-40e6-affa-519e8602c6e7"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250501"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>: Advise not to breastfeed. (<linkHtml href="#S8.2">8.2</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>: May impair fertility in males and females. (<linkHtml href="#S8.3">8.3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="4f48487c-cc71-4b7e-8178-8f8e6cb8f2bb"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="3272b5e9-e10d-4cba-8a71-8b301ce8eaf6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Based on the mechanisms of action, AVMAPKI FAKZYNJA CO-PACK can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S12.1">Clinical Pharmacology (12.1)</linkHtml>]</content>. There are no available data on the use of AVMAPKI FAKZYNJA CO-PACK in pregnant women to inform a drug-associated risk. Animal reproductive and developmental toxicity studies have not been conducted with avutometinib or defactinib; however, inhibition of either molecular pathway has been associated with embryo-fetal anomalies and lethality in animals. Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</paragraph>
                              <paragraph>The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="d6b55836-614b-4d1a-8bae-153cf740e3be"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="cd6fd6a7-df3d-46c8-a371-21d5c384ce7a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no data on the presence of avutometinib, defactinib, or their metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment with AVMAPKI FAKZYNJA CO-PACK and for 2 weeks after the last dose.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.3">
                     <id root="c2a79f16-8e32-41e1-8c82-411e4ccf730c"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of Reproductive Potential</title>
                     <text>
                        <paragraph>AVMAPKI FAKZYNJA CO-PACK can cause fetal harm when administered to a pregnant woman <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="04f8992a-7789-4441-a98b-6e53f55fa798"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Pregnancy Testing</content>
                              </paragraph>
                              <paragraph>Verify the pregnancy status of females of reproductive potential prior to initiating treatment with AVMAPKI FAKZYNJA CO-PACK.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d7845052-6441-4365-9b87-b358c81e71e2"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Contraception</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                           <component>
                              <section>
                                 <id root="37a0c8cb-75ba-4e35-8b23-a9d0d05bc701"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Females</content>
                                    </paragraph>
                                    <paragraph>Advise females of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 1 month after the last dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="17741fb9-ba23-4b04-bb2f-3dbdcdfd9da4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Males</content>
                                    </paragraph>
                                    <paragraph>Advise male patients with female partners of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 4 months after the last dose.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="432c7ad3-1443-41a2-812e-742c072b4967"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Infertility</content>
                              </paragraph>
                              <paragraph>Based on animal studies, AVMAPKI FAKZYNJA CO-PACK may impair fertility in females and males of reproductive potential. The effects on fertility were not reversible in animals <content styleCode="italics">[see <linkHtml href="#S13.1">Nonclinical Toxicology (13.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="2bc30a78-2deb-4424-8c26-ee4976c0fd5c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of AVMAPKI FAKZYNJA CO-PACK in pediatric patients has not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="0dd6933a-6062-4d78-95ba-80dc1d492ae8"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 136 patients in clinical studies of AVMAPKI FAKZYNJA CO-PACK, 29% were age 65 years or older. No overall differences in safety were observed between patients age 65 years or older and younger patients. Clinical studies of AVMAPKI FAKZYNJA CO-PACK did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="c4a58b48-5131-41b1-b843-fa31c88e08c2"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>AVMAPKI FAKZYNJA CO-PACK contains AVMAPKI (avutometinib) capsules co-packaged with FAKZYNJA (defactinib) tablets.</paragraph>
                  <paragraph>AVMAPKI capsules contain avutometinib, a kinase inhibitor. The chemical name of avutometinib is N-(3-Fluoro-4-{[4-methyl-7-(2-pyrimidinyloxy)-2H-chromen-2-on-3-yl]methyl}-2-pyridyl)-N'-methylsulfamide potassium salt. The molecular formula for avutometinib is C<sub>21</sub>H<sub>17</sub>FN<sub>5</sub>O<sub>5</sub>S (as potassium salt) and its molecular weight is 509.55. The chemical structure of avutometinib is shown below:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Avutometinib potassium is a white to pale yellow powder. It is practically insoluble in the pH range of 1 to 7 in aqueous media. The pKa is 7.02.</paragraph>
                  <paragraph>AVMAPKI capsules for oral administration contain 0.8 mg of avutometinib (equivalent to 0.864 mg as the avutometinib potassium salt) with the following inactive ingredients: magnesium stearate and mannitol in a hypromellose capsule shell (carrageenan, hypromellose, potassium chloride, purified water, and titanium oxide) printed with black ink (black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution).</paragraph>
                  <paragraph>FAKZYNJA tablets contain defactinib, a kinase inhibitor. The chemical name of defactinib is N-methyl-4-({4-[({3-methyl(methylsulfonyl)aminopyrazin-2-yl}methyl)amino]-5-(trifluoromethyl)pyrimidin-2-yl}amino)benzamide hydrochloride.  The molecular formula for defactinib is C<sub>20</sub>ClH<sub>22</sub>F<sub>3</sub>N<sub>8</sub>O<sub>3</sub>S (as hydrochloride [HCl] salt) and its molecular weight is 546.96. The chemical structure of defactinib is shown below:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM2"/>
                  </paragraph>
                  <paragraph>Defactinib hydrochloride is a white to pale yellow powder. It is very slightly soluble at pH 1 and practically insoluble in the pH range of 4.5 to 6.8 in aqueous media. The pKa is 3.81.</paragraph>
                  <paragraph>FAKZYNJA tablets are available for oral administration. Each FAKZYNJA tablet contains 200 mg defactinib (equivalent to 214.36 mg as the defactinib hydrochloride salt) and the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="avmapki-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="avmapki-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="d01d8843-afcf-4264-93eb-6c532d4c871a"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250501"/>
               <component>
                  <section ID="S12.1">
                     <id root="504b409b-b5b5-4a11-936b-94c0bb8077be"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="dbe27ea6-34b4-4397-9cca-68fcb1224def"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Avutometinib</content>
                              </paragraph>
                              <paragraph>Avutometinib is a MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents phosphorylation of MEK1/2 by RAF. RAF and MEK proteins are regulators of the RAS/RAF/MEK/ERK (MAPK) pathway. Avutometinib inhibited MEK1/2 and ERK1/2 phosphorylation and proliferation of tumor cell lines harboring KRAS mutations. Treatment of cancer cells with avutometinib increased the level of phosphorylated focal adhesion kinase (FAK).</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="107e9a39-5ffe-4761-8708-1a392f1ac00e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Defactinib</content>
                              </paragraph>
                              <paragraph>Defactinib is an inhibitor of FAK and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases. Defactinib inhibited FAK autophosphorylation in cancer cells <content styleCode="italics">in vitro</content> and in mouse xenograft models.</paragraph>
                              <paragraph>Avutometinib in combination with defactinib enhanced inhibition of cell proliferation <content styleCode="italics">in vitro</content> and anti-tumor activity in mouse tumor models including LGSOC.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="ab2e0b7c-5587-4143-bc12-38492f60671e"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Avutometinib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.</paragraph>
                        <paragraph>Defactinib exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="55080487-d33f-4421-b763-a12f358e1954"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>At the recommended doses for AVMAPKI FAKZYNJA CO-PACK, a mean increase in the QTc interval &gt;20 msec was not observed. For the 88 patients with PR interval measured in RAMP-201, the mean PR interval increased by 16 msec from baseline to Cycle 1 Day 15 4-hours post dose.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="08e29877-bdd5-42a1-b668-07e8582fd33d"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetics of avutometinib and defactinib were studied in healthy subjects and in patients with advanced solid tumors and are presented as mean (%CV) unless otherwise specified.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="48ec4afe-5681-4715-86dc-c24c81fa85f0"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Avutometinib</content>
                              </paragraph>
                              <paragraph>Avutometinib exhibits dose proportional increases peak plasma concentrations (C<sub>max</sub>) and area under the concentration time curve (AUC) with a single dose ranging from 0.1 mg to 5 mg (0.03 to 1.6 times the approved recommended dose). No significant accumulation of avutometinib was observed at the recommended dosage.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="6433c54f-6b63-4f3b-bce8-865434998e0a"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Defactinib</content>
                              </paragraph>
                              <paragraph>Defactinib exhibits dose proportional increases in C<sub>max</sub> and AUC with twice daily dosing ranging from 12.5 mg to 450 mg (0.06 to 2.25 times the approved recommended dosage). Defactinib steady-state plasma concentrations are reached in approximately 15 days. Defactinib accumulation is approximately 1.5-fold at the approved recommended dosage.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="10f5b7a0-7ac4-4b38-b58c-d95f1e0601bf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>The median time to avutometinib peak plasma concentration (T<sub>max</sub>) under fasted conditions is approximately 2 hours.</paragraph>
                              <paragraph>The median time to defactinib T<sub>max</sub> under fed conditions is approximately 4 hours.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                           <component>
                              <section>
                                 <id root="13dccbb5-9d00-4cfd-8f57-0723ddbd86f8"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>No clinically significant differences in avutometinib AUC were observed following administration with a high-fat meal. Avutometinib C<sub>max</sub> was decreased by 29% following administration with a high-fat meal (approximately 900 to 1000 calories, 50% fat).</paragraph>
                                    <paragraph>Defactinib AUC increased by 2.7-fold and C<sub>max</sub> increased by 1.9-fold following administration with a high-fat meal (approximately 900 to 1000 calories, 50% fat).</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="440c94b3-d5d6-4946-9413-ac1b4e3e3fa3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Avutometinib steady state apparent volume of distribution (V<sub>d</sub>) is 25 L (19%). Avutometinib human plasma protein binding is 99% <content styleCode="italics">in vitro</content>.</paragraph>
                              <paragraph>Defactinib steady state apparent V<sub>d</sub> is 1,560 L (59%). Defactinib human plasma protein binding is 90% <content styleCode="italics">in vitro</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="4f883a39-f059-4bcb-a24b-1cc7edfb697d"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Avutometinib estimated elimination half-life is 51 hours (28%) and the apparent oral clearance (CL/F) is 0.3 L/h (30%).</paragraph>
                              <paragraph>Defactinib estimated elimination half-life is 9 hours (171%) and the CL/F is 69 L/h (173%).</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                           <component>
                              <section>
                                 <id root="c9c43fb4-a119-4a2c-a436-6cd5a0b493b0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>Avutometinib is primarily metabolized by CYP3A4 and nonenzymatic degradation.</paragraph>
                                    <paragraph>Defactinib is metabolized primarily by CYP3A4 and CYP2C9.  Two major metabolites, N-desmethyl sulfonamide (M2) and N-desmethyl amide (M4), were identified in plasma.  M2 and M4 AUCs represent 92% and 28% of defactinib exposure, respectively. M2 is inactive and M4 is equipotent when compared to defactinib.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="0c914faa-7299-44d3-9edd-c15c991c2b63"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>After a single dose of radiolabeled avutometinib 2.4 mg (0.8 times the approved recommended dose), 39% (9.5% unchanged) of the dose was recovered in feces and 52% (3.2% unchanged) in urine.</paragraph>
                                    <paragraph>After a single dose of radiolabeled defactinib 400 mg (2 times the approved recommended dose), 87% (52% unchanged) of the dose was recovered in feces and 7.6% (0.8% unchanged) in urine.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="81dffb60-6795-4b73-afa5-b80f2c03d83c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of avutometinib were observed based on age (21 to 87 years), sex, race (84% White, 3% Black and 2% Asian), body weight (40 to 169 kg), mild and moderate renal impairment (CLcr 30 to 89 mL/min, estimated by Cockcroft-Gault), or mild hepatic impairment (AST &gt; ULN or total bilirubin &gt;1 × ULN to 1.5 × ULN). The effect of severe renal impairment (CLcr &lt; 30 mL/min) or moderate to severe hepatic impairment (AST or ALT ≥ 2.5 × ULN or total bilirubin ≥ 1.5 × ULN) on avutometinib pharmacokinetics is unknown.</paragraph>
                              <paragraph>No clinically meaningful differences in the pharmacokinetics of defactinib were observed based on age (21 to 87 years), sex, race (82% White, 3% Black and 2% Asian), body weight (40 to 169 kg), mild and moderate renal impairment (CLcr 30 to 89 mL/min), or mild hepatic impairment (AST &gt; ULN or total bilirubin &gt;1 × ULN to 1.5 × ULN). The effect of severe renal impairment (CLcr &lt; 30 mL/min) or moderate to severe hepatic impairment (AST or ALT ≥ 2.5 × ULN or total bilirubin ≥ 1.5 × ULN) on defactinib pharmacokinetics is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="719f941b-4a0c-415d-bca9-c8fb2950557c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                           <component>
                              <section>
                                 <id root="ea36e58a-08f4-44fe-b3ef-4291d3367f4c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Clinical Studies</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                                 <component>
                                    <section>
                                       <id root="35b4c42b-914d-41e8-9b80-6fc3badad88f"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Strong CYP3A4 Inhibitors:</content>
                                          </paragraph>
                                          <paragraph>No clinically significant differences in avutometinib pharmacokinetics were observed when used concomitantly with itraconazole (strong CYP3A4 inhibitor).</paragraph>
                                          <paragraph>Defactinib C<sub>max</sub> increased by 2.2-fold and AUC by 3.9-fold following concomitant use with itraconazole (strong CYP3A4 inhibitor) 200 mg daily for 10 days. M4 AUC increased by 2.2-fold and C<sub>max</sub> decreased by 6.8%.</paragraph>
                                       </text>
                                       <effectiveTime value="20250501"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="34477ecb-f911-4541-9424-cfeabeabd4cc"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Strong CYP3A4 Inducers:</content>
                                          </paragraph>
                                          <paragraph>Avutometinib AUC decreased by 34% with no clinically significant change in C<sub>max</sub> following coadministration with phenytoin (strong CYP3A4 inducer) three times daily for 23 days and a single dose of avutometinib 2.4 mg (0.8 times the approved recommended dose) on Day 17.</paragraph>
                                          <paragraph>Defactinib C<sub>max</sub> decreased by 83% and AUC by 87% following coadministration with phenytoin (strong CYP3A4 inducer) three times daily for 23 days and a single dose of defactinib 200 mg (1.0 times the approved recommended dose) on Day 14. M4 AUC decreased by 79% and C<sub>max</sub> decreased by 70%.</paragraph>
                                       </text>
                                       <effectiveTime value="20250501"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="d3aee82c-b244-442a-96ae-55819c021b9f"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Proton Pump Inhibitors (PPIs):</content>
                                          </paragraph>
                                          <paragraph>Defactinib displayed pH-dependent aqueous solubility <content styleCode="italics">[see <linkHtml href="#S11">Description (11)</linkHtml>]</content>. Defactinib AUC decreased by 79% and C<sub>max</sub> decreased by 85% following concomitant use of multiple doses of omeprazole (PPI) 40 mg daily. M4 AUC decreased by 83% and C<sub>max</sub> decreased by 88%.</paragraph>
                                       </text>
                                       <effectiveTime value="20250501"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="7a619b1d-7dcc-496c-9a7b-1719e6883e2c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">In Vitro Studies</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                                 <component>
                                    <section>
                                       <id root="65125e88-58a5-4d62-a8fc-534d10ee4bc5"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">CYP450 Enzymes:</content>
                                          </paragraph>
                                          <paragraph>Avutometinib is a CYP3A4 substrate, but not a substrate of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Avutometinib is not an inhibitor of CYP3A4, CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6. Avutometinib is not an inducer of CYP3A4, CYP2B6, and CYP1A2.</paragraph>
                                          <paragraph>Defactinib is a CYP3A4 and CYP2C9 substrate, but not a substrate of CYP1A2, CYP2B6, CYP2C8, CYP2C19, and CYP2D6. Defactinib is a reversible inhibitor of CYP3A4 and CYP2C9, but not CYP1A2, CYP2B6, CYP2C8, CYP2C19, and CYP2D6. Defactinib is a time-dependent inhibitor of CYP3A4.  Defactinib is an inducer of CYP2B6, and CYP1A2, but not CYP3A4.</paragraph>
                                       </text>
                                       <effectiveTime value="20250501"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="91372313-c485-4ac4-ae07-a03a4cc141a6"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">UGT Enzymes:</content>
                                          </paragraph>
                                          <paragraph>Defactinib may inhibit UGT1A1 at clinically relevant concentrations.</paragraph>
                                       </text>
                                       <effectiveTime value="20250501"/>
                                    </section>
                                 </component>
                                 <component>
                                    <section>
                                       <id root="a02cc609-cd9f-4a45-bed0-ba9716e71f1d"/>
                                       <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                       <text>
                                          <paragraph>
                                             <content styleCode="italics">Transporter Systems:</content>
                                          </paragraph>
                                          <paragraph>Avutometinib is a substrate of P-gp and BCRP, but not a substrate of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 and OCT2. Avutometinib is not an inhibitor of P-gp, BCRP, MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1 and OCT2.</paragraph>
                                          <paragraph>Defactinib is a BCRP and P-gp substrate, but not a substrate of MATE1, MATE2-K, OAT1, OAT3, OATP1B1, OATP1B3, OCT1, and OCT2. Defactinib is an inhibitor of P-gp, BCRP, OATP1B1, OATP1B3, and MATE2-K, but not an inhibitor of MATE1, OAT1, OAT3, OCT1, and OCT2.</paragraph>
                                       </text>
                                       <effectiveTime value="20250501"/>
                                    </section>
                                 </component>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="d3abdc4c-e5af-412c-9b00-d40c4268520a"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250501"/>
               <component>
                  <section ID="S13.1">
                     <id root="4e88bfa1-00f9-4566-9815-73801e3a3433"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="23b31eb5-3df0-4750-a3b1-aa92b30938f3"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Avutometinib</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                           <component>
                              <section>
                                 <id root="185e9b4d-8a1b-4c36-833a-a30ee0d3a812"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Carcinogenesis</content>
                                    </paragraph>
                                    <paragraph>Carcinogenicity studies have not been conducted with avutometinib.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="7439c299-a9d1-4ab5-ae3f-504cc7662304"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Mutagenesis</content>
                                    </paragraph>
                                    <paragraph>Avutometinib was not mutagenic in the bacterial reverse mutagenesis (Ames) assay and was not clastogenic in an <content styleCode="italics">in vitro</content> Chinese hamster lung chromosome aberration assay or an <content styleCode="italics">in vivo</content> rat bone marrow micronucleus assay.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="08dc5eb4-e1db-4628-abe3-47068b57a3ef"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Impairment of Fertility</content>
                                    </paragraph>
                                    <paragraph>Dedicated fertility studies have not been conducted with avutometinib. In repeat dose toxicity studies, avutometinib was administered orally once daily for up to 13-weeks duration in rats and monkeys. In female rats, atrophy of the ovary was observed at doses ≥ 0.04 mg/kg/day (approximately ≥ 0.25 times the human exposure at the recommended dose based on AUC). Atrophy of the uterus and thinning of the mucosa and increased single cell necrosis of the mucosal epithelium in the vagina were observed at 0.16 mg/kg/day (0.5 times the human exposure at the recommended dose based on AUC). In female monkeys, thinning of the vaginal mucosa was observed at doses ≥ 0.02 mg/kg/day (≥ 0.7 times the human exposure at the recommended dose based on AUC). All findings were reversible.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="32f33d18-7124-46a5-b502-4ebb3f0dbbff"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Defactinib</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                           <component>
                              <section>
                                 <id root="4af28504-a3d7-4257-9176-54826692d462"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Carcinogenesis</content>
                                    </paragraph>
                                    <paragraph>Carcinogenicity studies have not been conducted with defactinib.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="a51123fe-8d3c-456a-b9d6-039cd8be8db3"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Mutagenesis</content>
                                    </paragraph>
                                    <paragraph>Defactinib was not mutagenic in the bacterial reverse mutagenesis (Ames) assay and was not clastogenic in an <content styleCode="italics">in vitro</content> Chinese hamster lung cell chromosome aberration assay. Defactinib was positive in the <content styleCode="italics">in vitro</content> micronucleus assay through an aneugenic mechanism and in the <content styleCode="italics">in vivo</content> rat bone marrow micronucleus assay.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="9c95f9cf-ee0c-4988-b392-d463e9721f43"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Impairment of Fertility</content>
                                    </paragraph>
                                    <paragraph>Dedicated fertility studies have not been conducted with defactinib. In male rats administered defactinib for up to 13 weeks, small prostate, seminal vesicle, and testes, decreased prostate weight, diffuse tubule degeneration/atrophy of the testes and sperm granuloma of the epididymis were observed at doses ≥ 125 mg/kg/day (below the human exposure at the recommended dose based on AUC). At the end of the recovery period, findings in the testes were observed.</paragraph>
                                    <paragraph>In male dogs administered defactinib for up to 13 weeks, increased prostate and testes weights and testicular degeneration and cellular debris in the epididymis were observed at doses ≥ 1 mg/kg/day (below the human exposure at the recommended dose based on AUC). At the end of the recovery period, findings in the testes and epididymis that included cellular debris, duct dilation, and hypospermia were observed.</paragraph>
                                 </text>
                                 <effectiveTime value="20250501"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S13.2">
                     <id root="4d82f34a-d467-43be-b329-c10ceb310703"/>
                     <code code="34091-9" codeSystem="2.16.840.1.113883.6.1" displayName="ANIMAL PHARMACOLOGY &amp; OR TOXICOLOGY SECTION"/>
                     <title>13.2 Animal Toxicology and/or Pharmacology</title>
                     <effectiveTime value="20250501"/>
                     <component>
                        <section>
                           <id root="cd525d9c-c015-478c-9426-e507b9bb10f4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Avutometinib</content>
                              </paragraph>
                              <paragraph>In repeat-dose toxicity studies up to 13-weeks duration in rats and monkeys, tissue mineralization in multiple organs was observed at doses ≥ 0.01 mg/kg/day and 0.03 mg/kg/day, respectively (≥ 0.06 and 1.4 times the human exposure at the recommended dose based on AUC, respectively) as well as increased inorganic phosphorus in rats.</paragraph>
                              <paragraph>In a cardiovascular telemetry study in monkeys, a single oral dose of avutometinib increased systolic, diastolic, and mean blood pressure at 1 mg/kg (approximately 15 times the human C<sub>max</sub> at the recommended dose). In the repeat-dose toxicology studies up to 13-weeks duration in rats, myocardial degeneration and necrosis were observed at doses ≥ 0.01 mg/kg/day (below the human exposure at the recommended dose based on AUC).</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="aadeb3e7-6127-4d2a-9bc1-061c4df0a6a5"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Defactinib</content>
                              </paragraph>
                              <paragraph>In a cardiovascular telemetry study in dogs, a single oral dose of defactinib decreased myocardial contractility at doses ≥ 5 mg/kg (approximately the human exposure at the recommended dose based on AUC) and increased ventricular systolic, diastolic and mean blood pressure at doses ≥ 25 mg/kg/day (≥ 2.7 times the human exposure at the recommended dose based on AUC). In the 13-week repeat-dose toxicology study in dogs, myocardium hypertrophy was observed at doses ≥ 1 mg/kg/day (below the human exposure at the recommended dose based on AUC) at the end of the dosing and recovery periods.</paragraph>
                           </text>
                           <effectiveTime value="20250501"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="f79617dd-e7d6-47ee-af4a-94b2890cded1"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of AVMAPKI FAKZYNJA CO-PACK was evaluated in RAMP-201 (NCT04625270), an open-label, multicenter study that included 57 adult patients with measurable <content styleCode="italics">KRAS</content>-mutated recurrent LGSOC. Patients were required to have received at least one prior systemic therapy, including a platinum-based regimen. <content styleCode="italics">KRAS</content> mutation status was determined by prospective local testing using next generation sequencing (NGS) or polymerase chain reaction of tumor tissue specimens. Patients were excluded if they were candidates for debulking surgery, were on treatment with warfarin, had an active skin disorder requiring systemic therapy within the past year, or had an ocular disorder (including a history of retinal pathology, an active or chronic visually significant corneal disorder, or a history of glaucoma).</paragraph>
                  <paragraph>Patients received AVMAPKI 3.2 mg orally twice weekly for the first 3 weeks out of a 4-week cycle and FAKZYNJA 200 mg orally twice daily for the first 3 weeks out of a 4-week cycle until disease progression or unacceptable toxicity. The major efficacy outcome measure was overall response rate (ORR) assessed by blinded independent review committee (BIRC) according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. An additional efficacy outcome measure was duration of response (DoR). Tumor response assessments occurred every 8 weeks for the first 72 weeks and every 12 weeks thereafter.</paragraph>
                  <paragraph>The median age was 60 years (range: 29 to 87); 75% were White, 3.5% were Asian, 3.5% were Black or African American, and 18% did not have race reported; 3.5% of patients were Hispanic or Latino; 72% had an ECOG PS of 0 and 28% had ECOG PS of 1. The <content styleCode="italics">KRAS</content> mutations identified by local testing were G12V (53%), G12D (35%), Q61H (3.5%), G12C (1.8%), G12R (1.8%), A146V (1.8%), and mutations not otherwise specified at G12x (1.8%) and on codon 12/13 (1.8%). Fourteen percent of patients had received 1 prior line of systemic therapy, 25% of patients had received 2 prior lines, 18% had received 3 prior lines and 40% had received more than 3 prior lines of systemic therapy. All patients had received prior platinum-based chemotherapy, 84% received prior hormonal therapy (as maintenance or treatment), 40% received prior bevacizumab and 21% received a prior MEK inhibitor.</paragraph>
                  <paragraph>Efficacy results are presented in Table 5.</paragraph>
                  <table width="85%">
                     <caption>Table 5 Efficacy Results in RAMP-201</caption>
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="center" valign="top"/>
                     <thead>
                        <tr>
                           <th styleCode="Lrule Rrule"/>
                           <th styleCode="Rrule">AVMAPKI FAKZYNJA CO-PACK<br/>N = 57</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">
                              <content styleCode="bold">Confirmed Overall Response Rate (95% CI)</content>
                              <footnote>ORR 95% CI calculated using Clopper-Pearson method</footnote>
                           </td>
                           <td styleCode="Rrule">44%<br/>(31,58)</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Complete response</td>
                           <td styleCode="Rrule">3.5%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td styleCode="Lrule Rrule">  Partial response</td>
                           <td styleCode="Rrule">40%</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="2" styleCode="Lrule Rrule">
                              <content styleCode="bold">Duration of Response (DoR)</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">  Range (months)</td>
                           <td styleCode="Rrule">3.3, 31.1</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>The tumor <content styleCode="italics">KRAS</content> mutations observed in the 25 responders were A146V, G12D, G12R, G12V, and Q61H.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="196789a1-03c5-4856-88c5-60c5de11033c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>AVMAPKI FAKZYNJA CO-PACK is supplied in a carton that contains:</paragraph>
                  <table width="85%">
                     <col width="50%" align="left" valign="top"/>
                     <col width="50%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td styleCode="Lrule Rrule Botrule">AVMAPKI capsules in a 24-count bottle with child-resistant closure<br/>(NDC 71779-660-02)</td>
                           <td styleCode="Rrule">NDC 71779-623-01</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule">FAKZYNJA tablets in a 42-count bottle with child-resistant closure<br/>(NDC 71779-630-01)</td>
                           <td styleCode="Rrule"/>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="disc">
                     <item>AVMAPKI (avutometinib) 0.8 mg capsules are supplied as white capsules with "6766" printed on the cap and the strength "0.8 mg" printed on the body in black ink in a bottle containing 24 capsules. The bottle contains a desiccant that should not be discarded.</item>
                     <item>FAKZYNJA (defactinib) 200 mg tablets are supplied as white to off-white, oval and debossed with "VS2" on one side of the tablet in a bottle containing 42 tablets. </item>
                  </list>
               </text>
               <effectiveTime value="20250501"/>
               <component>
                  <section>
                     <id root="949f79bb-b3d9-4f98-be9c-cf39da41546a"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>Store AVMAPKI capsules and FAKZYNJA tablets refrigerated at 2°C to 8°C (36°F to 46°F) in their original bottles.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="1eb23f9e-b7e9-4f19-80fc-9d55872ac601"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Patient Information).</paragraph>
               </text>
               <effectiveTime value="20250501"/>
               <component>
                  <section>
                     <id root="80208f15-57be-48ea-8662-229cd717ff48"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Ocular Toxicities</content>
                        </paragraph>
                        <paragraph>Inform patients of the need for eye exams before and during treatment with AVMAPKI FAKZYNJA CO-PACK.</paragraph>
                        <paragraph>Advise patients to contact their healthcare provider if they experience any visual changes, pain, or inflammation around their eye(s) <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c2acc339-02f8-472c-a416-a6cfad7da8df"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Serious Skin Toxicities</content>
                        </paragraph>
                        <paragraph>Inform patients that skin reactions have occurred during treatment with AVMAPKI FAKZYNJA CO-PACK.</paragraph>
                        <paragraph>Advise patients to use prophylactic topical steroids and oral antibiotics <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content> and to limit unnecessary exposure to sunlight with application of daily sunscreen (sun protection factor [SPF] ≥ 30) <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Advise patients to contact their healthcare provider if they develop a rash, progressively worsening skin reactions, or blistering of the skin or mouth <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c8b226ed-b4a5-4e9c-81a6-6350b2b1ca1c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity</content>
                        </paragraph>
                        <paragraph>Advise patients that they will need to undergo laboratory testing to monitor their liver function.</paragraph>
                        <paragraph>Advise patients to contact their healthcare provider for signs or symptoms of liver dysfunction <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="68cfd75d-78a0-47fb-877d-89990b2b0cc7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Rhabdomyolysis</content>
                        </paragraph>
                        <paragraph>Inform patients that they will need to undergo laboratory testing to monitor CPK levels.</paragraph>
                        <paragraph>Advise patients to contact their healthcare provider for signs or symptoms of rhabdomyolysis <content styleCode="italics">[see <linkHtml href="#S5.4">Warnings and Precautions (5.4)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="92b8215d-e952-47e4-98a1-04d4cfbd8f8c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions</content>
                        </paragraph>
                        <paragraph>Inform patients to avoid concomitant use of AVMAPKI FAKZYNJA CO-PACK with PPIs or H2 receptor antagonists.</paragraph>
                        <paragraph>Advise patients that if use of an acid reducing agent cannot be avoided, to take FAKZYNJA 2 hours prior to, or 2 hours after, the administration of a locally acting antacid <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="938ce937-4e1e-4d1f-a51f-35d446785ebe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Embryo-Fetal Toxicity</content>
                        </paragraph>
                        <paragraph>Advise pregnant women and females of reproductive potential of the potential risk to a fetus.</paragraph>
                        <paragraph>Advise females to inform their healthcare providers of a known or suspected pregnancy. Advise females of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 1 month after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with AVMAPKI FAKZYNJA CO-PACK and for 4 months after the last dose <content styleCode="italics">[see <linkHtml href="#S5.5">Warnings and Precautions (5.5)</linkHtml> and <linkHtml href="#S8.1">Use in Specific Population (8.1</linkHtml>, <linkHtml href="#S8.3">8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="13a33a86-7631-4de3-b486-e52ef11625fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Lactation</content>
                        </paragraph>
                        <paragraph>Advise women not to breastfeed during treatment with AVMAPKI FAKZYNJA CO-PACK and for 2 weeks after the last dose <content styleCode="italics">[see <linkHtml href="#S8.2">Use in Specific Populations (8.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="3f21888e-9865-4521-b814-05e16676c942"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Infertility</content>
                        </paragraph>
                        <paragraph>Advise males and females of reproductive potential that AVMAPKI FAKZYNJA CO-PACK may impair fertility <content styleCode="italics">[see <linkHtml href="#S8.3">Use in Specific Populations (8.3)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250501"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="36c3c407-982b-4724-818b-d975442ddc90"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for and Distributed by:<br/>Verastem, Inc.<br/>Needham, Massachusetts 02494<br/>1-877-878-6662</paragraph>
                  <paragraph>© 2025 Verastem, Inc.</paragraph>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section>
               <id root="3934d970-842d-46ca-87eb-29cf90d7e099"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <text>
                  <table width="100%">
                     <col width="3%" align="left" valign="top"/>
                     <col width="22%" align="left" valign="top"/>
                     <col width="5%" align="left" valign="top"/>
                     <col width="15%" align="left" valign="top"/>
                     <col width="2%" align="left" valign="top"/>
                     <col width="3%" align="left" valign="top"/>
                     <col width="5%" align="left" valign="top"/>
                     <col width="5%" align="left" valign="top"/>
                     <col width="10%" align="left" valign="top"/>
                     <col width="30%" align="left" valign="top"/>
                     <thead>
                        <tr>
                           <th colspan="10" align="center" styleCode="Lrule Rrule" valign="top">PATIENT INFORMATION<br/>AVMAPKI™ FAKZYNJA™ CO-PACK (ave-MAP-kee Fak-zin-jah koh-pak)<br/>(avutometinib capsules; defactinib tablets)<br/>co-packaged for oral use</th>
                        </tr>
                     </thead>
                     <tfoot>
                        <tr>
                           <td colspan="9" align="left" valign="top">        This Patient Information has been approved by the U.S. Food and Drug Administration.</td>
                           <td align="right" valign="top">Issued: 05/2025        </td>
                        </tr>
                        <tr>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                           <td/>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr styleCode="Botrule">
                           <td colspan="10" styleCode="Lrule Rrule">
                              <content styleCode="bold">What is AVMAPKI FAKZYNJA CO-PACK?</content>
                              <br/>AVMAPKI FAKZYNJA CO-PACK is a prescription medicine used to treat adults who have: 									<list listType="unordered" styleCode="disc">
                                 <item>low-grade serous ovarian cancer (LGSOC) that has come back (recurrent), <content styleCode="bold">and</content>
                                 </item>
                                 <item>LGSOC with an abnormal <content styleCode="italics">KRAS</content> gene, <content styleCode="bold">and</content>
                                 </item>
                                 <item>previously been treated with medicine for their cancer.</item>
                              </list>									It is not known if AVMAPKI FAKZYNJA CO-PACK is safe and effective in children. 									</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="10" styleCode="Lrule Rrule">
                              <content styleCode="bold">Before taking AVMAPKI FAKZYNJA CO-PACK, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>have a history of eye or vision problems</item>
                                 <item>have had severe skin reactions</item>
                                 <item>have liver problems</item>
                                 <item>are pregnant or plan to become pregnant. AVMAPKI FAKZYNJA CO-PACK can harm your unborn baby.<br/>
                                    <content styleCode="bold">Females who are able to become pregnant</content>:<list listType="unordered" styleCode="circle">
                                       <item>Your healthcare provider should do a pregnancy test before you start treatment with AVMAPKI FAKZYNJA CO- PACK.</item>
                                       <item>You should use effective birth control (contraception) during treatment and for 1 month after the last dose of AVMAPKI FAKZYNJA CO-PACK.</item>
                                       <item>Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with AVMAPKI FAKZYNJA CO-PACK.</item>
                                    </list>
                                    <content styleCode="bold">Males with a female partner who is able to become pregnant</content>:<list listType="unordered" styleCode="circle">
                                       <item>You should use effective birth control (contraception) during treatment and for 4 months after the last dose of AVMAPKI FAKZYNJA CO-PACK.</item>
                                    </list>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. It is not known if AVMAPKI FAKZYNJA CO-PACK passes into your breast milk. Do not breastfeed during treatment and for 2 weeks after the last dose of AVMAPKI FAKZYNJA CO-PACK.</item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take</content>, including prescription and over-the-counter medicines, vitamins, and herbal supplements. AVMAPKI FAKZYNJA CO-PACK may affect the way other medicines work, and other medicines may affect how AVMAPKI FAKZYNJA CO-PACK works.<br/>
                              <content styleCode="bold">Especially tell your healthcare provider if you take</content>: 									<list listType="unordered" styleCode="disc">
                                 <item>proton pump inhibitors (PPIs) or H2 receptor antagonists</item>
                                 <item>a blood thinner called warfarin</item>
                              </list>									Know the medicines you take. Keep a list of them with you to show your healthcare provider and pharmacist when you get a new medicine.<br/>
                              <content styleCode="bold">How should I take AVMAPKI FAKZYNJA CO-PACK?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Take AVMAPKI FAKZYNJA CO-PACK exactly as directed by your healthcare provider.</item>
                                 <item>Do not change your dose or stop taking AVMAPKI FAKZYNJA CO-PACK without talking to your healthcare provider.</item>
                                 <item>If you develop certain side effects your healthcare provider may change your dose, temporarily stop, or completely stop your treatment with AVMAPKI FAKZYNJA CO-PACK.</item>
                              </list>									Take AVMAPKI capsules and FAKZYNJA tablets with food. 									<list listType="unordered" styleCode="disc">
                                 <item>If you vomit after taking AVMAPKI capsules or FAKZYNJA tablets, do not take an additional dose. Take the next scheduled dose as prescribed by your healthcare provider.</item>
                              </list>
                              <content styleCode="bold">AVMAPKI capsules</content>: 									<list listType="unordered" styleCode="disc">
                                 <item>Take each dose at the same time.</item>
                                 <item>Swallow the capsules whole. Do not chew, break, or open the capsules.</item>
                                 <item>If you miss a dose of AVMAPKI by more than 24 hours, skip the missed dose and take the next scheduled dose as prescribed by your healthcare provider. Do not take two doses at the same time to make up for a missed dose.</item>
                              </list>
                              <content styleCode="bold">FAKZYNJA tablets:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Swallow the tablets whole. Do not chew, break, or crush the tablets.</item>
                                 <item>If you take antacids, take FAKZYNJA tablets 2 hours before or 2 hours after taking the antacid.</item>
                                 <item>If you miss a dose of FAKZYNJA by more than 6 hours, skip the missed dose and take the next scheduled dose as prescribed by your healthcare provider. Do not take two doses at the same time to make up for a missed dose.</item>
                              </list>									Before and during treatment with AVMAPKI FAKZYNJA CO-PACK, your health care provider will give you medicines to apply to your face, scalp, neck, upper chest and upper back, and antibiotic medicines to take by mouth to help prevent skin reactions. 									</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="10" styleCode="Lrule Rrule">
                              <content styleCode="bold">What should I avoid while taking AVMAPKI FAKZYNJA CO-PACK?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Limit your time in the sun. AVMAPKI FAKZYNJA CO-PACK can make your skin sensitive to the sun (photosensitivity) and the light from sunlamps and tanning beds. You may burn more easily and get a severe sunburn. Apply daily sunscreen with a Sun Protection Factor (SPF) of 30 or greater and wear a hat and clothes that cover your skin to protect against sunburn. Talk to your healthcare provider if you get a sunburn.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="10" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the possible side effects of AVMAPKI FAKZYNJA CO-PACK? AVMAPKI FAKZYNJA CO-PACK may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">eye problems.</content> Eye problems are common with AVMAPKI FAKZYNJA CO-PACK and can be severe. Your healthcare provider will send you to see an eye care professional before starting treatment, during treatment, and for any new or worsening eye problems. Tell your healthcare provider if you get any new or worsening eye problems including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="3">
                              <list listType="unordered" styleCode="circle">
                                 <item>changes in vision, such as blurred vision, double vision, or vision loss</item>
                                 <item>dry eye(s)</item>
                                 <item>eye and eyelid inflammation, including redness, swelling, and itching</item>
                              </list>
                           </td>
                           <td colspan="6" styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>eye pain</item>
                                 <item>new or increased floaters (small dark spots or squiggly lines that float across your vision)</item>
                                 <item>light hurting eyes or seeing flashes of light</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="10" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">severe skin reactions</content>. Skin reactions are common with AVMAPKI FAKZYNJA CO-PACK and can be severe or life threatening. Tell your healthcare provider if you develop any new or worsening skin reactions including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td>
                              <list listType="unordered" styleCode="circle">
                                 <item>skin rash or acne</item>
                                 <item>dry skin</item>
                                 <item>itching</item>
                              </list>
                           </td>
                           <td colspan="5">
                              <list listType="unordered" styleCode="circle">
                                 <item>blisters on your skin</item>
                                 <item>redness or swelling of your face, hands, or soles of your feet</item>
                              </list>
                           </td>
                           <td colspan="3" styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>blisters or sores in your mouth</item>
                                 <item>peeling of your skin</item>
                                 <item>skin infection</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="10" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">liver problems.</content> Liver problems are common with AVMAPKI FAKZYNJA CO-PACK and can be severe. Treatment with AVMAPKI FAKZYNJA CO-PACK can increase the level of aspartate aminotransferase, alanine aminotransferase, and bilirubin in your blood. Your healthcare provider will do blood tests before starting each treatment cycle and during treatment to check your liver function. Tell your healthcare provider if you get any signs or symptoms of severe liver problems including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="5">
                              <list listType="unordered" styleCode="circle">
                                 <item>yellowing of your skin or the white part of your eyes</item>
                                 <item>itchy skin</item>
                                 <item>feeling very tired</item>
                                 <item>flu-like symptoms</item>
                              </list>
                           </td>
                           <td colspan="4" styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>nausea or vomiting</item>
                                 <item>upper right side stomach pain</item>
                                 <item>dark or tea colored urine</item>
                                 <item>bleeding or bruising more easily than normal</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="10" styleCode="Lrule Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>
                                    <content styleCode="bold">muscle problems (rhabdomyolysis).</content> AVMAPKI FAKZYNJA CO-PACK may cause muscle problems that can be severe. Treatment with AVMAPKI FAKZYNJA CO-PACK can increase the level of an enzyme in your blood called creatine phosphokinase (CPK) and can be a sign of muscle damage. Your healthcare provider will perform blood tests to check your levels of CPK before starting each treatment cycle and during treatment. Tell your healthcare provider if you get any signs or symptoms of increased CPK including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule"/>
                           <td colspan="2">
                              <list listType="unordered" styleCode="circle">
                                 <item>weakness or difficulty moving arms and legs</item>
                              </list>
                           </td>
                           <td colspan="5">
                              <list listType="unordered" styleCode="circle">
                                 <item>muscle or bone aches or pain that does not go away</item>
                              </list>
                           </td>
                           <td colspan="2" styleCode="Rrule">
                              <list listType="unordered" styleCode="circle">
                                 <item>dark, red colored urine or decreased urine output</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="10" styleCode="Lrule Rrule">
                              <content styleCode="bold">The most common side effects of AVMAPKI FAKZYNJA CO-PACK include</content>:</td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule" colspan="2">
                              <list listType="unordered" styleCode="disc">
                                 <item>nausea</item>
                                 <item>tiredness</item>
                                 <item>increased aspartate aminotransferase</item>
                                 <item>diarrhea</item>
                                 <item>swelling in the body (edema)</item>
                              </list>
                           </td>
                           <td colspan="3">
                              <list listType="unordered" styleCode="disc">
                                 <item>decreased hemoglobin</item>
                                 <item>increased alanine aminotransferase</item>
                                 <item>vomiting</item>
                                 <item>increased blood bilirubin</item>
                                 <item>increased triglycerides</item>
                              </list>
                           </td>
                           <td colspan="4">
                              <list listType="unordered" styleCode="disc">
                                 <item>stomach-area pain</item>
                                 <item>acid reflux</item>
                                 <item>increased alkaline phosphatase</item>
                                 <item>decreased platelets</item>
                                 <item>constipation</item>
                                 <item>shortness of breath</item>
                              </list>
                           </td>
                           <td styleCode="Rrule">
                              <list listType="unordered" styleCode="disc">
                                 <item>cough</item>
                                 <item>urinary tract infection</item>
                                 <item>decreased lymphocytes</item>
                                 <item>decreased neutrophils</item>
                                 <item>proteinuria</item>
                              </list>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="10" styleCode="Lrule Rrule">AVMAPKI FAKZYNJA CO-PACK may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if this is a concern for you.<br/>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.<br/>These are not all of the possible side effects of AVMAPKI FAKZYNJA CO-PACK. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="10" styleCode="Lrule Rrule">
                              <content styleCode="bold">How should I store AVMAPKI FAKZYNJA CO-PACK?</content>
                              <list listType="unordered" styleCode="disc">
                                 <item>Store AVMAPKI capsules and FAKZYNJA tablets in the refrigerator between 36°F to 46°F (2°C to 8°C) in the original bottles.</item>
                                 <item>The AVMAPKI capsules and FAKZYNJA tablets come in child-resistant bottles.</item>
                              </list>
                              <content styleCode="bold">Keep AVMAPKI FAKZYNJA CO-PACK and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr styleCode="Botrule">
                           <td colspan="10" styleCode="Lrule Rrule">
                              <content styleCode="bold">General information about the safe and effective use of AVMAPKI FAKZYNJA CO-PACK.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use AVMAPKI FAKZYNJA CO-PACK for a condition for which it was not prescribed. Do not give AVMAPKI FAKZYNJA CO- PACK to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about AVMAPKI FAKZYNJA CO-PACK that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td colspan="10" styleCode="Lrule Rrule">
                              <content styleCode="bold">What are the ingredients in AVMAPKI FAKZYNJA CO-PACK?</content>
                              <br/>
                              <content styleCode="bold">AVMAPKI (avutometinib) capsules:<br/>Active ingredient</content>: avutometinib<br/>
                              <content styleCode="bold">Inactive ingredients</content>: magnesium stearate, mannitol, black iron oxide, butyl alcohol, dehydrated alcohol, isopropyl alcohol, potassium hydroxide, propylene glycol, purified water, shellac, and strong ammonia solution. The capsule shell contains carrageenan, hypromellose, potassium chloride, purified water, and titanium oxide.<br/>
                              <content styleCode="bold">FAKZYNJA (defactinib) tablets:</content>
                              <br/>
                              <content styleCode="bold">Active ingredient</content>: defactinib<br/>
                              <content styleCode="bold">Inactive ingredients</content>: lactose monohydrate, magnesium stearate, microcrystalline cellulose and sodium starch glycolate.<br/>Manufactured for and Distributed by: Verastem, Inc., Needham, Massachusetts 02494<br/>© 2025  Verastem, Inc.<br/>For more information, go to www.AvmapkiFakzynjaCo-Pack.com or call 1-877-878-6662.</td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20250501"/>
            </section>
         </component>
         <component>
            <section>
               <id root="9f47e1aa-5290-469e-981b-2e5f729aacb8"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - Kit Carton</title>
               <text>
                  <paragraph>NDC 71779-623-01<br/>Rx only</paragraph>
                  <paragraph>AVMAPKI™<br/>(avutometinib) capsules<br/>0.8 mg</paragraph>
                  <paragraph>FAKZYNJA™<br/>(defactinib) tablets<br/>200 mg</paragraph>
                  <paragraph>CO-PACK</paragraph>
                  <paragraph>This carton contains:</paragraph>
                  <paragraph>AVMAPKI™ (avutometinib):<br/>1 bottle of 24 capsules</paragraph>
                  <paragraph>FAKZYNJA™ (defactinib):<br/>1 bottle of 42 tablets</paragraph>
                  <paragraph>Prescribing Information</paragraph>
                  <paragraph>Patient Dosing Card</paragraph>
                  <paragraph>KEEP REFRIGERATED</paragraph>
                  <paragraph>VERASTEM™<br/>ONCOLOGY</paragraph>
                  <renderMultiMedia referencedObject="MM3"/>
               </text>
               <effectiveTime value="20250501"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>PRINCIPAL DISPLAY PANEL - Kit Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="avmapki-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="0adc5471-b8e1-4002-874b-eabbee75ee8a"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 0.8 mg Capsule Bottle Label</title>
               <text>
                  <paragraph>NDC 71779-660-02<br/>Rx only</paragraph>
                  <paragraph>AVMAPKI™<br/>(avutometinib) capsules<br/>0.8 mg</paragraph>
                  <paragraph>KEEP<br/>REFRIGERATED</paragraph>
                  <paragraph>24 capsules</paragraph>
                  <paragraph>773622</paragraph>
                  <paragraph>Recommended Dosage:<br/>See printed Prescribing<br/>Information inside the<br/>carton.</paragraph>
                  <paragraph>Manufactured for:<br/>Verastem, Inc.<br/>Needham, MA 02494 USA</paragraph>
                  <paragraph>For information, call toll-free<br/>1-877-878-6662 or visit us at<br/>www.AvmapkiFakzynjaCo-Pack.com</paragraph>
                  <paragraph>VERASTEM™<br/>ONCOLOGY</paragraph>
                  <paragraph>© 2025 Verastem, Inc.</paragraph>
                  <renderMultiMedia referencedObject="MM4"/>
               </text>
               <effectiveTime value="20250501"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>PRINCIPAL DISPLAY PANEL - 0.8 mg Capsule Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="avmapki-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="3cdb2ff6-6213-4576-afa1-61c201ced4e5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label</title>
               <text>
                  <paragraph>NDC 71779-630-01<br/>Rx only</paragraph>
                  <paragraph>FAKZYNJA™<br/>(defactinib) tablets<br/>200 mg</paragraph>
                  <paragraph>KEEP REFRIGERATED</paragraph>
                  <paragraph>42 tablets</paragraph>
                  <paragraph>VERASTEM™<br/>ONCOLOGY</paragraph>
                  <paragraph>Recommended Dosage: See<br/>printed Prescribing Information<br/>inside the carton.</paragraph>
                  <paragraph>Manufactured for:<br/>Verastem, Inc.<br/>Needham, MA 02494 USA</paragraph>
                  <paragraph>For information, call toll-free<br/>1-877-878-6662 or visit us at<br/>www.AvmapkiFakzynjaCo-Pack.com</paragraph>
                  <paragraph>© 2025 Verastem, Inc.</paragraph>
                  <paragraph>773624</paragraph>
                  <renderMultiMedia referencedObject="MM5"/>
               </text>
               <effectiveTime value="20250501"/>
               <component>
                  <observationMedia ID="MM5">
                     <text>PRINCIPAL DISPLAY PANEL - 200 mg Tablet Bottle Label</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="avmapki-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>